Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2022 | Letermovir prophylaxis to prevent infection after HSCT

Michael Boeckh • 28 Oct 2022
COSTEM 2022
General Letermovir

Michael Boeckh, MD, PhD, Fred Hutchinson Cancer Research Center, Washington, WA, provides an overview of current views surrounding the use of letermovir as secondary prophylaxis after hematopoietic stem cell transplantation (HSCT). Whilst the antiviral drug may be useful for patients with a high viral load or who have high-grade immunosuppression, there is no reliable data on its efficacy and additional research is required to elucidate its long-term effects. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Michael Boeckh

1:00
Identifying post-transplant secondary pulmonary infections
Michael Boeckh • 28 Oct 2022

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals